Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.
Mamand, Sami
Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. [electronic resource] - Scientific reports 09 2018 - 14216 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
2045-2322
10.1038/s41598-018-32634-5 doi
Apoptosis--drug effects
Cell Differentiation--drug effects
Cell Line, Tumor
Cell Movement--drug effects
Chemokine CXCL12--metabolism
Humans
Jurkat Cells
Lymphoma, T-Cell, Peripheral--drug therapy
Phosphorylation--drug effects
Protein-Tyrosine Kinases--antagonists & inhibitors
Receptors, CXCR4--metabolism
Signal Transduction--drug effects
T-Lymphocytes, Helper-Inducer--drug effects
Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. [electronic resource] - Scientific reports 09 2018 - 14216 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
2045-2322
10.1038/s41598-018-32634-5 doi
Apoptosis--drug effects
Cell Differentiation--drug effects
Cell Line, Tumor
Cell Movement--drug effects
Chemokine CXCL12--metabolism
Humans
Jurkat Cells
Lymphoma, T-Cell, Peripheral--drug therapy
Phosphorylation--drug effects
Protein-Tyrosine Kinases--antagonists & inhibitors
Receptors, CXCR4--metabolism
Signal Transduction--drug effects
T-Lymphocytes, Helper-Inducer--drug effects